Mesenchymal stem cells (MSCs) represent a new therapeutic paradigm for
a number of diseases because they possess unique biological characteristics such as
multipotency, immunomodulation and production of cytokines. Currently, 425 MSC
based clinical trials have been conducted for at least 12 kinds of pathological conditions,
with many completed trials demonstrating the safety and efficacy of MSCs.
Here, we provide an overview of the clinical status of MSCs by searching the public
clinical trials database http://clinicaltrials.gov. Particularly, the role of MSCs in clinical
trials to treat bone defects and injuries is highlighted.
Keywords: Bone defects, clinical transition, differentiation, immunomodulation, mesenchymal stem cells, secretome.
Rights & PermissionsPrintExport